Posts by Cheikh Kane, Ph.D.
Cheikh Kane, PhD is currently the VP BioPharma Sciences at KCAS Bio where his teams are focused on bioanalytical LBA (PK, ADA and BM), Cell Based NAB (Neutralizing antibody assays) and Molecular to support drug development programs for biologics. Dr. Kane has more than two decades of experience in the bioanalytical and biomarker fields and related strategies spanning from Biopharmaceutical/Biotechnology industry to the CRO business. At KCAS Bio he leads strategic and technical initiatives that drive innovation in bioanalytical, biomarker and molecular sciences and expands the company’s capabilities.
Posters & Papers
This case study describes the development and validation of an ELISA method to quantify total antibody (tAb) from PYX-201, an investigational antibody-drug conjugate (ADC) developed by Pyxis Oncology. The assay was validated in rat and monkey plasma and used to support preclinical studies and an IND filing. The method…
Posters & Papers
This case study describes the development and validation of an ELISA method to quantify total antibody (tAb) from PYX-201, an investigational antibody-drug conjugate (ADC) developed by Pyxis Oncology. The assay was validated in rat and monkey plasma and used to support preclinical studies and an IND filing. The method…
Posters & Papers
Please download this poster, “Automating Selection for Incurred Sample Reanalysis: A Meta-Analytical-Based Algorithm for Error Reduction”